Inside the $230 billion our new Longevity Biotech Report says the pipeline is already worth – no regulatory rewrite required.
Telomir’s oncology compound helped fish with age-related retinal damage see better and moved two aging-linked markers toward ...
Coya Therapeutics hits its 100th ALS trial enrollment and publishes new preclinical data, both pointing to the same ...
Phil Newman analyzes Oura’s IPO and lawsuit, movement context in dementia, GenFlow dog trial, Rentosertib aging clocks, and ...
Enveda raised $311 million to push its AI-discovered medicines forward, including one aimed at life after GLP-1 drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results